Fulcrum Therapeutics Inc reports results for the quarter - Earnings Summary

Fulcrum Therapeutics

13/11/2024 15:25

* Fulcrum Therapeutics Inc  FULC.OQ  reported a quarterly
adjusted
loss of 35 cents​​ per share for the quarter , higher than the
same quarter last year, when the company reported EPS of -39
cents.  The mean expectation of nine analysts for the quarter
was for a loss of 41 cents per share. Wall Street expected
results to range from -47 cents to -37 cents per share.
    * Reported revenue was zero​; analysts expected zero. 
    * Fulcrum Therapeutics Inc's reported EPS for the quarter
was a
loss of 35 cents​.
    * The company reported a quarterly loss of $21.7 million.
    * Fulcrum Therapeutics Inc shares had risen by 2.0% this
quarter and lost 46.1% so far this year.

FORECAST CHANGES
    * The mean earnings estimate of analysts had risen by
about 1.8%
in the last three months.​ 
    * In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company.

RECOMMENDATIONS
    * The current average analyst rating on the shares is "hold"
and
the breakdown of recommendations is 2 "strong buy" or "buy," 5
"hold" and 1 "sell" or "strong sell." 
    * The average consensus recommendation for the biotechnology
&
medical research peer group is also "hold"

Wall Street's median 12-month price target for Fulcrum
Therapeutics Inc is $4.00 
This summary was machine generated from LSEG data November 13 at
03:25 p.m. UTC. ​All figures in US dollars unless otherwise
stated. (For questions concerning the data in this report,
contact Estimates.Support@lseg.com. For any other questions or
feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Sep. 30 2024      -0.41          -0.35          Beat
 Jun. 30 2024      -0.01          0.87           Beat
 Mar. 31 2024      -0.44          -0.43          Beat
 Dec. 31 2023      -0.43          -0.40          Beat